145 related articles for article (PubMed ID: 28422745)
21. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
22. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
[TBL] [Abstract][Full Text] [Related]
24. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
25. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
27. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
28. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
29. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings.
El Mubarak MA; Leontari I; Efstathia G; Vrettos EI; Shaikh AK; Konstantinos SE; Danika C; Kalofonos HP; Tzakos AG; Sivolapenko GB
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1092():515-523. PubMed ID: 30008308
[TBL] [Abstract][Full Text] [Related]
31. Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy.
Chen FH; Chiang CS; Wang CC; Fu SY; Tsai CS; Jung SM; Wen CJ; Lee CC; Hong JH
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1512-21. PubMed ID: 21621344
[TBL] [Abstract][Full Text] [Related]
32. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.
Conley SJ; Gheordunescu E; Kakarala P; Newman B; Korkaya H; Heath AN; Clouthier SG; Wicha MS
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2784-9. PubMed ID: 22308314
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
35. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
36. Dynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model.
Song Y; Cho G; Suh JY; Lee CK; Kim YR; Kim YJ; Kim JK
Korean J Radiol; 2013; 14(4):589-96. PubMed ID: 23901316
[TBL] [Abstract][Full Text] [Related]
37. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.
Silva E; Gatalica Z; Vranic S; Basu G; Reddy SK; Voss A
Breast J; 2015; 21(2):205-7. PubMed ID: 25639617
[No Abstract] [Full Text] [Related]
38. Ageing-related responses to antiangiogenic effects of sunitinib in atherosclerosis-prone mice.
Meehan B; Garnier D; Dombrovsky A; Lau K; D'Asti E; Magnus N; Rak J
Mech Ageing Dev; 2014 Sep; 140():13-22. PubMed ID: 25068886
[TBL] [Abstract][Full Text] [Related]
39. Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.
Torok S; Vegvari A; Rezeli M; Fehniger TE; Tovari J; Paku S; Laszlo V; Hegedus B; Rozsas A; Dome B; Marko-Varga G
Br J Pharmacol; 2015 Feb; 172(4):1148-63. PubMed ID: 25363319
[TBL] [Abstract][Full Text] [Related]
40. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
